Fruth Investment Management Eli Lilly & CO Transaction History

Fruth Investment Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$592.2 - $792.28 $29,610 - $39,614	-50 Reduced 2.52%	1,935 $1.51 Million
Q4 2023 Jan 18, 2024	SELL	$525.19 - $619.13 $60,396 - $71,199	-115 Reduced 5.48%	1,985 $1.16 Million
Q2 2023 Jul 25, 2023	SELL	$350.74 - $468.98 $35,074 - $46,898	-100 Reduced 4.55%	2,100 $984,000
Q1 2023 Apr 26, 2023	SELL	$310.63 - $364.82 $15,531 - $18,241	-50 Reduced 2.22%	2,200 $755,000
Q1 2022 Apr 12, 2022	BUY	$234.69 - $291.66 $11,030 - $13,708	47 Added 2.13%	2,250 $644,000
Q3 2018 Oct 10, 2018	BUY	$85.86 - $107.31 $189,149 - $236,403	2,203 New	2,203 $236,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Fruth Investment Management, based on Form 13F filings with the SEC.

Stay updated on Fruth Investment Management with notifications on news.